Table 2. Analysis of tumor response and survival according to the continuation or not of trastuzumab from the second-line of chemotherapy.

	Overall Population N = 104	Second-line therapy without trastuzumab N = 65	Second-line therapy with trastuzumab N = 39	P-value
Tumor response
Complete response	3 (2.9%)	1 (1.5%)	2 (5.1%)
Partial response	6 (5.7%)	2 (3.1%)	4 (10.3%)
Stable disease	24 (23.1%)	12 (18.5%)	12 (30.8%)
Progression disease	58 (55.8%)	40 (61.5%)	18 (46.1%)
Not evaluable	13 (12.5%)	10 (15.4%)	3 (7.7%)
Objective response rate *	9.9%	5.4%	16.7%	0.08
Disease control rate *	36.3%	27.3%	50.0%	0.03
Median PFS, mo. (95% CI)	2.7 (2.3-4.0)	2.3 (2.0-3.0)	4.4 (2.4-5.6)	0.002
6-mo. PFS rate (95% CI)	20.8% (13.5-29.3)	13.5% (6.5-23.1)	30.2% (16.2-45.4)
Median OS, mo. (95% CI)	7.1 (5.5-9.4)	6.1 (4.8-8.3)	12.6 (5.5-18.5)	0.001
1-yr OS rate (95% CI)	29.1% (19.9-38.9)	17.9% (9.3-28.8)	48.4% (29.8-64.7)

^* Objective response rate and disease control rate were evaluated in patients who had measurable disease (n=91).

The P values for comparison of objective response and disease control rates were assessed using the Chi2 test.

The P value for the comparison of time to event endpoints was assessed using the log-rank test.

Abbreviations: mo., months; yr, year